Tetragon Partners GP portfolio
Concentrated managerType not verifiedPortfolio as of Jun 30, 2026 (Q2 2026) · filed with the SEC on Aug 13, 2026 · data updated on Nov 5, 2026 · Q2 2026 13F (filing) ↗ · all its 13F filings ↗
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
Tetragon Partners GP reported a $614M portfolio of 32 positions to the SEC as of the end of Q2 2026. Its largest positions are PATH, KGEI, AUTL. During the quarter it opened Alkami Technology and Celcuity and exited Praxis Precision Medicines and Axsome Therapeutics.
Sections with a free account
What it reported after the quarter end (Q2 2026)
The 13F shows the portfolio as of Jun 30, 2026. Since then Tetragon Partners GP has filed these own trades with the SEC (Form 4, when it owns more than 10% of a company or holds a role in it) and stakes above 5% (13D and 13G). It is not everything it did: only what it must report before the next 13F.
Stake reported in the company · event of Jun 30, 2026 · filed Jul 15, 2026 · filing ↗
What changed this quarter
31 positions with a change (5 new, 15 added to, 5 trimmed, 6 sold); also, 1 exited through an acquisition or merger. 10 are listed here: those of 0.5 points of the portfolio or more (up to 12).
- UiPath+23%more sharesIncreased55.0% → 54.8%
- Warner Bros. Discovery−73%fewer sharesReduced5.0% → 1.1%
- Alkami Technology+1.8 ppof portfolioNew— → 1.8%
- Relay Therapeutics+214%more sharesIncreased0.4% → 1.7%
- Celcuity+1.1 ppof portfolioNew— → 1.1%
- Praxis Precision Medicines−0.8 ppof portfolioSold out1.0% → —
- Ionis Pharmaceuticals+133%more sharesIncreased0.6% → 1.3%
- Definium Therapeutics+43%more sharesIncreased0.7% → 2.2%
- Axsome Therapeutics−0.6 ppof portfolioSold out0.7% → —
- MBX Biosciences+40%more sharesIncreased0.9% → 1.8%
The figure on the right: for positions added to or trimmed, the change in the number of shares (%); for new and sold ones, the points of the portfolio moved (pp). Below, the portfolio weight before → after. Traded weight: what it bought or sold, excluding price effects.
Top holdings
- UiPathPATH54.8%
- Kolibri Global EnergyKGEI5.5%
- Autolus TherapeuticsAUTL2.5%
- LyftLYFT2.4%
- Definium TherapeuticsDFTX2.2%
- WorkivaWK2.0%
- SprinklrCXM1.8%
- MBX BiosciencesMBX1.8%
- Alkami TechnologyALKT1.8%
- Celldex TherapeuticsCLDX1.8%
- Relay TherapeuticsRLAY1.7%
- Arrowhead PharmaceuticalsARWR1.7%
- PharvarisPHVS1.7%
- Alkermes plc.ALKS1.6%
- ImmunovantIMVT1.6%
“Since”: first quarter of the current run, unbroken until today. In the details, prices are the quarter-end prices of the quarters in which it added shares, per the 13F. The manager may have bought at any price within each quarter; the SEC only publishes the value at quarter end.
Portfolio by sector
- ● Information Technology 61%
- ● Health Care 30%
- ● Energy 6%
- ● Industrials 2%
- ● Communication Services 1%
How its portfolio changed (8 quarters)
Q2 2026: 32
Q2 2026: 77%
Q2 2026: 12.5%
Traded turnover: the weight it bought plus the weight it sold in the quarter, divided by two, excluding price moves. The plain “turnover” in the header does include that effect. With a free account: the full history and sectors over time.
13F filings with amendments or confidential positions
- 13F Q4 2024 ↗filed Feb 14, 2025Amendment of Feb 21, 2025 (replaces the original) ↗
Declared options (7)
Besides stocks, Tetragon Partners GP declared 7 calls (they gain if it rises) with a notional of $20.7M. The 13F reports the value of the underlying shares, not the premium paid, so these figures look large and are not added to the portfolio. Nor does it say whether the option is bought or written, or its strike or expiry: it may be a hedge.
- CALLAxsome TherapeuticsAXSM$8.6M
- CALLUltragenyx PharmaceuticalRAREnew this quarter$3.3M
- CALLSilence TherapeuticsSLNnew this quarter$3.3M
- CALLKaryopharm TherapeuticsKPTI$2.4M
- CALLAgios PharmaceuticalsAGIOnew this quarter$1.9M
- CALLTenax TherapeuticsTENXnew this quarter$1.1M
- CALLAmylyx PharmaceuticalsAMLXnew this quarter$153K
Stakes above 5% (13D/13G)
Companies where this filer reported holding 5% or more of the shares. It is the figure from its latest filing on each one; history since December 2024.
How we classify it
Type not verified. It meets the portfolio criteria of a concentrated manager, but its type is not verified: we found no official document that is enough to say what kind of entity it is. It may be an investment firm, but also an adviser adding up client accounts, a bank or a family vehicle. It counts in the tallies like the rest; keep that in mind when reading it. How the type is assigned
Managers of a similar size
A 13F portfolio value between a third and three times this one, whatever the type of filer. It is not a comparison of what they hold.
- Steginsky Capital$610M
- Robert RobottiInvestment firm · $620M
- RIT Capital Partners$621M
- Mason Capital ManagementSingle-position portfolio · $607M
- Conifer Management, L.L.CInvestment firm · $607M
- Shah Capital ManagementInvestment firm · $605M